IceCure Medical Ltd. (NASDAQ:ICCM) Given Average Recommendation of “Hold” by Analysts

Shares of IceCure Medical Ltd. (NASDAQ:ICCM) have been given a consensus recommendation of “Hold” by the five brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $62.70.

A number of equities research analysts recently commented on ICCM shares. Wall Street Zen upgraded shares of IceCure Medical to a “sell” rating in a research report on Sunday, July 12th. Alliance Global Partners assumed coverage on IceCure Medical in a research report on Monday, May 4th. They set a “buy” rating on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of IceCure Medical in a research note on Friday, July 17th. Finally, Maxim Group reduced their price target on IceCure Medical from $90.00 to $30.00 and set a “buy” rating for the company in a report on Thursday, May 14th.

Institutional Investors Weigh In On IceCure Medical

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC purchased a new stake in shares of IceCure Medical during the 4th quarter worth $67,000. Concurrent Investment Advisors LLC purchased a new position in shares of IceCure Medical in the 4th quarter valued at about $48,000. Finally, Virtu Financial LLC acquired a new stake in shares of IceCure Medical in the fourth quarter valued at about $39,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

IceCure Medical Stock Up 7.0%

Shares of NASDAQ:ICCM opened at $3.51 on Wednesday. The company has a market cap of $12.04 million, a price-to-earnings ratio of -0.49 and a beta of 0.47. The firm’s 50-day simple moving average is $4.03 and its 200-day simple moving average is $10.06. IceCure Medical has a fifty-two week low of $2.12 and a fifty-two week high of $42.00.

IceCure Medical (NASDAQ:ICCM) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.03). The firm had revenue of $0.91 million for the quarter, compared to analyst estimates of $1.34 million. IceCure Medical had a negative return on equity of 211.73% and a negative net margin of 441.60%. On average, research analysts forecast that IceCure Medical will post -3.51 EPS for the current year.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.